curacle co.,ltd. (KOSDAQ:365270)

South Korea · Delayed Price · Currency is KRW

9,380.00

+930.00 (11.01%)

At close: Oct 16, 2026

Market Cap	207.83B +44.6%
Revenue (ttm)	8.24B +627.5%
Net Income	-7.59B
EPS	-377.58
Shares Out	22.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,411
Open	8,700.00
Previous Close	8,450.00
Day's Range	8,440.00 - 9,560.00
52-Week Range	4,400.00 - 20,750.00
Beta	2.10
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2016

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 365270

Full Company Profile

Financial Performance

In 2025, curacle co.,ltd.'s revenue was 7.10 million, a decrease of -99.57% compared to the previous year's 1.63 billion. Losses were -18.11 billion, 21.7% more than in 2024.

Financial Statements